Potential Use of Autologous & Allogeneic Mesenchymal Stem Cells in

Status Recruiting

Clinical Trial Summary

The prevalence of Multiple System Atrophy (MSA) is reported to be between 3.4 - 4.9 cases per 100,000 population. The estimated average incidence is 0.6 - 0.7 cases per 100,000 people per year. Many patients are not diagnosed properly during their lifetime because of the difficulty in differentiating MSA from other disorders. Approximately 29 - 33% of patients with isolated late onset cerebellar ataxia and 8 - 10% of patients with parkinsonism will develop MSA. There are currently no therapies that can cure or stop the progression of the disease. The current pharmacological therapy is only to relieve symptoms. Mesenchymal stem cells (MSC) are considered an efficient source of cells for therapy, because they can be safely harvested and transplanted to donors or patients, have low immunogenicity, and have broad therapeutic potential. Results from preliminary preclinical and clinical trials indicate the potential of MSC-based treatment in meeting several key aspects of neurodegeneration. Stem cell-based therapy for neurodegenerative diseases aims to stop clinical damage by regenerating and by providing local support for damaged tissue, in addition after transplantation, MSCs have been shown to be capable of penetrating the lesion area and thus have great potential use as a means of administering therapeutic agents. The subjects of this study were patients who experienced possible MSA based on the consensus clinical criteria for MSA. There will be three treatment groups with a total sample of 5 subjects each. Group 1 will receives MSC-Adipose Autologous with doses 2x50 million cells intratechally. Group 2 will receives MSC-Umbilical Cord Allogeneic with doses 2x 50 million cells intratechally. Group 3 will receives MSC-Umbilical Cord Allogeneic with doses 2x50 million cells intratechally and 2x10cc secretome MSC from Adipose Intravenously. Clinical improvement will be evaluated using the UMSARS scale, PET-Scans, MRI, DaTScan, IGF-1, BDNF, Sympathetic skin respons (SSR), EMG, Composite Autonomic Severity Score (CASS), High definition-Optical coherence tomography (HD-OCT), ERG, VEP, Log MAR chart, Ishihara test and side adverse effect on MSC. This study is divided into six timeframes : Before an implantation, First Month after second implantation, Third month after secondary implantation, Sixth month after second implantation, Ninth month after second implantation and Twelve month after second implantation. The differences between the test variables are then used as an indicator to assess clinical improvement within the subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04876326
Study type	Interventional
Source	Indonesia University
Contact
Status	Recruiting
Phase	N/A
Start date	October 5, 2020
Completion date	October 5, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03593512` - Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy	N/A
Recruiting	`NCT03648905` - Clinical Laboratory Evaluation of Chronic Autonomic Failure
Active, not recruiting	`NCT05699460` - Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Recruiting	`NCT02897063` - Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure	Phase 1
Not yet recruiting	`NCT00758849` - Fipamezole in Neurogenic Orthostatic Hypotension	Phase 2
Completed	`NCT01155492` - Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease	N/A
Recruiting	`NCT04431713` - Exenatide Once-weekly as a Treatment for Multiple System Atrophy	Phase 2
Completed	`NCT04184063` - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)	Phase 2
Recruiting	`NCT05121012` - Synaptic Loss in Multiple System Atrophy
Terminated	`NCT03589976` - A Futility Trial of Sirolimus in Multiple System Atrophy	Phase 2
Recruiting	`NCT04706234` - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Completed	`NCT00368199` - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes	N/A
Recruiting	`NCT04472130` - Neurodegenerative Diseases Registry
Recruiting	`NCT04680065` - GDNF Gene Therapy for Multiple System Atrophy	Phase 1
Completed	`NCT03753763` - Safinamide for Multiple System Atrophy (MSA)	Phase 2
Recruiting	`NCT04250493` - Insulin Resistance in Multiple System Atrophy	N/A
Recruiting	`NCT06072105` - Medical Decision Making in Multiple System Atrophy	N/A
Terminated	`NCT02149901` - Water and Sudafed in Autonomic Failure	Early Phase 1
Terminated	`NCT00997672` - Lithium in Multiple System Atrophy	Phase 2
Completed	`NCT00465790` - Research of Biomarkers in Parkinson Disease	Phase 0

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms